GlassScriptPhysician profile
Samuel Alonzo Ramirez
NPI 1538190244
$16,407.12
in general payments reported to CMS, 2019-2025
60 companies · $2,575 in 2025
The $2,575 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,773 · 2020: $2,248 · 2021: $2,881 · 2022: $2,478 · 2023: $2,150 · 2024: $2,303 · 2025: $2,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,028.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,034.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,864.19 | 2019-2025 | |
| Amgen INC. | $1,633.46 | 2019-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,483.40 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $783.83 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $682.99 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $641.92 | 2019-2025 | |
| Amarin Pharma, INC. | $637.57 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $551.13 | 2019-2025 | Jardiance |
| Antares Pharma, INC. | $352.77 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Astellas Pharma US INC | $313.78 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $310.30 | 2020-2025 | Verquvo, Steglatro, Belsomra |
| Dexcom, INC. | $309.10 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $308.05 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $298.04 | 2024-2025 | Voquezna |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.